Our Company
Overview

At United Health Products we develop, produce, and market innovative wound care products based upon our proprietary hemostatic absorbable gauze technology. Our technology is marketed under the brand names HemoStyp®, HemoStyp Trauma Gauze™, HemoStrip™, BooBoo Strips™, NikFix™, and other customized private label brand names.

We are customer driven. Our products are distributed worldwide and we support our customers with products and ideas that help to improve the health and care of the people they serve.

The fundamental principles guiding the development of HemoStyp Gauze will remain a constant. They define our commitment to developing products that function the way they are intended, are manufactured to the very highest standards, achieve benchmark levels of performance, and inspire confidence with their use.

Company Snapshot Hemostatic Products Market

Corporate Address
10624 S Eastern Ave, STE A209
Henderson, NV 89052
877.358.3444
info@unitdheathproductsinc.com

Publicly Traded
OTCQB: UEEC

Manufacturing//Distribution Faciities
Niwot, CO
Hainesport, NJ
El Segundo, CA

Market Segments
Trauma, Dental, Dialysis, Veterinary Medicine

Hemostasis is a process which causes bleeding to stop. It is the first stage of wound healing. The Global Hemostats Market is segmented into 5 major types, namely thrombin based hemostats, combination agents, oxidized regenerated cellulose based hemostats, gelatin based hemostats and collagen based hemostats. HemoStyp is an oxidized regenerated cellulose product.

On the basis of application, the market is segmented into surgery and wound closure and on the basis of end users, the market is classified into hospitals, community healthcare, ambulatory centers, and clinics. The hospital segment is expected to dominate the market for the foreseeable future.

The global hemostats market is expected to exceed USD 4.0 billion by 2024 from USD 2.7 billion in 2016. Some of the major factors driving the market for hemostats market are increasing number of surgeries, technological advancement, increasing healthcare expenditure, and infrastructure. These factors are increasing the demand for different heomostatic agents.

We believe our Company is well positioned to capitalize on the expanding market for hemostatic products with an inexpensive, highly effective, and all-natural product. In addition, in a healthcare industry under increasing pressure to reduce costs, HemoStyp represents a viable alternative to other higher priced hemostats.